Martin Zeiger

Mr. Martin Zeiger is SVP-Strategic Business Development at Barr Pharmaceuticals, Inc. and Adjunct Partner at Signet Healthcare Partners LLC.
He is on the Board of Directors at BioPro Pharmaceutical, Inc., Accu-Break Pharmaceuticals, Inc., and PLIVA dd.
Prior to joining Signet Healthcare Partners, Mr. Zeiger was a Senior Vice President at Barr Laboratories, Inc. Before Barr, he was Executive Vice President and General Counsel at Rugby Laboratories (a privately held generic drug company) until its acquisition by Marion Merrill Dow, Inc. in 1993.
He continued as a Vice President for Marion and its successor Company, Hoechst Marion Roussel, Inc. He was honored by Generic Pharmaceutical Industry Association at its March 2004 Annual Meeting as a generic industry founder.
Prior to joining pharmaceutical manufacturing companies, he served as Vice President General Counsel for Jack Eckerd Corp.
and Senior Vice President for Revco D.S., Inc. both major drug store retailers.
Mr. Zeiger is currently a Director of BioPro, Cedarburg Pharmaceuticals and the Larry King Cardiac Foundation and is a member of the supervisory board for Pliva Pharmaceuticals, a $2 billion pharmaceutical company recently acquired by Barr Laboratories.
He has several years of experience in many aspects of management in the pharmaceutical industry, both branded and generic.
Mr. Zeiger received his LLB and JD from St.John’s University School of Law, where he served as Publications Editor of the Law Review.
He is an attorney, admitted to practice in the State of New York.